Non-Cystic Fibrosis Bronchiectasis
Intervention of Interest For questions please contact info@icer.org. View the Key Stakeholder List.
Research Type: Assessment
Spinal Muscular Atrophy
Interventions of Interest For questions please contact info@icer.org. View the Key Stakeholder List.
Multiple Sclerosis: SPMS
Interventions of Interest For questions please contact info@icer.org. View the Key Stakeholder List.
Retinitis Pigmentosa
Interventions of Interest For questions please contact info@icer.org. View the Key Stakeholder List.
Acute Pain
Interventions of Interest The independent appraisal committee vote was split on the net health benefit of suzetrigine compared to non-systemic therapies; suzetrigine has potential to be cost-saving due to avoided future cases of opioid use disorder. Final Documents For questions please contact info@icer.org. View the Key Stakeholder List. ICER’s Chief Medical Officer David Rind, MD […]
Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
Interventions of Interest The independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for tabelecleucel when compared to usual care; tabelecleucel would achieve common thresholds for cost-effectiveness if priced between $143,900 to $273,700 per treatment cycle. Final Documents For questions or to request a Spanish translated Report-at-a-Glance or ICER […]
Transthyretin Amyloid Cardiomyopathy
Interventions of Interest The independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for tafamidis, acoramidis, and vutrisiran when compared to no disease-specific therapy. Tafamidis and acoramidis would achieve common thresholds for cost-effectiveness if priced between $13,600 to $39,000 per year. Final Documents For questions please contact info@icer.org. View […]
Anemia in Myelodysplastic Syndrome
Interventions of Interest An independent appraisal committee voted that the current evidence is not adequate to demonstrate net health benefits for imetelstat added to best supportive care when compared to best supportive care alone. Imetelstat would meet common thresholds of cost effectiveness if priced between $94,800 to $113,000 per year. The therapy currently priced at […]
Chronic Obstructive Pulmonary Disease
Interventions of Interest An independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for ensifentrine added to maintenance therapy compared to maintenance therapy alone. ICER calculated a health-benefit price benchmark (HBPB) for ensifentrine between $7,500 to $12,700 per year, and the therapy is priced at $35,400 per year Final […]
Post-Traumatic Stress Disorder
Interventions of Interest Independent appraisal committee voted that current evidence is not adequate to demonstrate superior net health benefits for MDMA-AP compared to short-term trauma-focused psychotherapies. Click here for “Five Fast Facts on ICER and our PTSD Report.” For questions or to request a Spanish translated Report-at-a-Glance or ICER Snapshot for this assessment, please contact info@icer.org. […]